Nateglinide has 26 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Alcohol, Amiodarone, Clonidine. Patients taking Nateglinide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 26
- Moderate
- 25
Moderate (25)
- Nateglinide + Alcohol— May increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and increased glucose mon…
- Nateglinide + Amiodarone— CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and…
- Nateglinide + Clonidine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
- Nateglinide + Corticosteroids— May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and…
- Nateglinide + Fluconazole— CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and…
- Nateglinide + Glucomannan— May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia.
- Nateglinide + Guanethidine— May increase blood-glucose-lowering effect and blunt hypoglycemia symptoms; dose adjustment and monitoring required.
- Nateglinide + Gymnema Sylvestre— Herbal product that may increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia.
- Nateglinide + Lanreotide— Somatostatin analogue that may reduce blood-glucose-lowering effect and increase susceptibility to hyperglycemia. Dose i…
- Nateglinide + Methandrostenolone— Anabolic hormone that may increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia.
- Nateglinide + Monoamine Oxidase Inhibitors (Maois)— May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increa…
- Nateglinide + Nonselective Beta-Adrenergic Antagonists— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
- Nateglinide + Octreotide— Somatostatin analogue that may reduce blood-glucose-lowering effect and increase susceptibility to hyperglycemia. Dose i…
- Nateglinide + Phenytoin— CYP inducer that may reduce blood-glucose-lowering effect and increase susceptibility to hyperglycemia. Dose increases a…
- Nateglinide + Reserpine— May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.
- Nateglinide + Rifampin— CYP inducer that may reduce blood-glucose-lowering effect and increase susceptibility to hyperglycemia. Dose increases a…
- Nateglinide + Salicylates— May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia. Dose reductions and increa…
- Nateglinide + Somatropin— May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and…
- Nateglinide + St. John'S Wort— CYP inducer that may reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia.
- Nateglinide + Sulfinpyrazone— CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and…
- Nateglinide + Teriflunomide— Teriflunomide may increase exposure of nateglinide. Consider reducing dose and monitor patients closely.
- Nateglinide + Thiazides— May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and…
- Nateglinide + Thioctic Acid— May increase blood-glucose-lowering effect of nateglinide and susceptibility to hypoglycemia.
- Nateglinide + Thyroid— May reduce blood-glucose-lowering effect of nateglinide and increase susceptibility to hyperglycemia. Dose increases and…
- Nateglinide + Voriconazole— CYP2C9 inhibitor that may increase blood-glucose-lowering effect and susceptibility to hypoglycemia. Dose reductions and…